StockData

Cryoport vs Lifecore Biomedical

CYRX and LFCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CYRX and LFCR compare

Cryoport is the larger company, worth 4.1 times as much as Lifecore Biomedical ($1000M against $242M).

Cryoport grew revenue faster over the last twelve months (12.1% versus 0.47% for Lifecore Biomedical).

Cryoport keeps more of each dollar of sales as profit, with a net margin of −20.1% compared with −30.0% at Lifecore Biomedical.

Cryoport scores higher on the StockData Score (11 against 4 for Lifecore Biomedical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCYRXLFCR
Size and price
Market cap$1000M$242M
Share price$19.74$6.39
Change, 1 year128%−19.7%
Change, 5 years−70.3%−26.3%
Beta (5Y)1.432.00
Employees738382
StockData Score
Total score11 (better)4
Valuation score11
Growth score3 (better)0
Performance score3 (better)2
Health score4 (better)1
Dividend score00
Valuation
P/S5.4×1.9× (better)
P/B2.0×–
FCF yield−2.0% (better)−5.6%
Fair value$16.22–
Margin of safety−21.7%–
Growth
Revenue growth (TTM)12.1% (better)0.47%
Revenue growth, 5Y average17.5% (better)−4.2%
Net income growth (TTM)−147% (better)−422%
EPS growth (TTM)−164% (better)−485%
Profitability
Gross margin47.1% (better)31.3%
Operating margin−21.2%−13.4% (better)
Net margin−20.1% (better)−30.0%
FCF margin−10.7%−10.6% (better)
Return on equity−7.4%–
Return on invested capital−33.0%–
Financial health
Debt / equity0.00–
Interest coverage−18.8×−0.8× (better)
Current ratio2.083.87 (better)
Altman Z-score1.40 (better)−0.17
Piotroski F-score55
Dividends and buybacks
Buyback yield–−9.9%
Shareholder yield0.00% (better)−9.9%
Ownership
Held by institutions93.9%67.1%
Held by insiders3.6%46.1%
Insider net buying, 12 months−$6.3M–
Superinvestors holding–1
Short interest, % of float7.1%8.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.